Other than ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and fit sufficient to tolerate FCR therapy, may still be excellent candidates with the latter, With all the profit currently being this treatment may be concluded in 6 months whilst ibrutinib has to be taken indefinitely. This feature could well be specifically worthwhile for no